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Leukocytes play an importaDt rote in the develop-
ment of diueminated intravaecular coaeuIation (DIC). 
In the reperfueion phue or OLT a DIC·li.ke flituation 
haa been deecribed and has been held re8pOnaible tor 
the high blood 1088 during tbis phase. 
We inveaticated the role olleukocytes in the patho-
,ene8i& 01 DIe in OLT by meuuring the leukocytic 
mediatora releaeed upon activation (cathepam B, eI ... 
tase, TNF, neopterin) ud tbe levels 01 thrombin-anti. 
thrombin m (TAT) comple:a.ea, seen 8IJ marken 01 pro-
thrombin activation. Arterial blood sampies were 
taken at 10 dift'erent time pointe durine and alter OLT. 
Sampies were also taken of the perfuBate releued 
from the liver patt vein durin, the tluahing procedure 
before the reperfuaion phase. Aprotinin wu given ... 
continuoua infuaion (0.2-0.4 MiIL KlUIhr) and it. 
plaama levell!l were determined. 
Sipülicantly elevated levels of neopterin (llS-fold; 
P<O.Ol), cathepein B (440-fold; P<O.Ol) in the perfuaate, 
aa compared with the ayatemic circulation, u weU aa 
their aigniticent iDcreases in the early reperfuaion 
phase auggested that they were releaaed by the aratt 
liver. This wu paralleled by elevated levels of elutue 
U.3-fold, P<O.(6), TNF (l.5-fold, P:::NS), end TAT com-
pleses (l .... foldi Pdl.l) in the pertusate. Sipülicant 
correlatiol18 could be identifted between the param-
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etera of leukocyte activation and TAT compleses. 
whereaa no correlation waa observed between eny of 
the parametera inveatigated end the aprotinin levels. 
Our results atrongly indieate arelease of leukoeytic 
mediatora trom the palt liver during its reperfuaion 
which seema to be related to the parallely increaaed 
prothrombin activatioD. No correlation could be seen 
between levels of aprotinin and levela of leukocytic 
mediatora. 
Leukocytes plsy an imporlant role in the development of 
dissemina~ intravsscular coagulation (DIe),· as shown in 
sepsis and promyelocytic leukemia·8.Bsociated DIe. Several 
mediaton are relea.aed upon stimulation of different leuko-
cytic subpopulations. TNFo:, an antitumoral cytokine pro-
duced by activated monocytes and macrophages as weil aa 
from peripheral T cells (J ). promotes the adherence and 
tr8ß8nUgration of granulocytes and monocytes to endothe-
lium and induces tissue fact.or synthesis in monocytes and 
endothelial cells (2 ). Furthermore, recent studies have pro-
posed the role ofTNF in Die (3 ). In OLT, TNF has been seen 
to precede the clinical manifestation of liver allograft rejec· 
tion (4, 5) and first-week TNF levels are believed to be useful 
predictors of long-term graft outeome (5 ). 
Neopterin is a pyrazino-pyrimidine compound derived 
from guanosine triphosphate within the biosynthetic path-
wa.y of tetrahydrobiopterin~an important cofactor for tyro-
sine and tryptophan hydroxylation. It plays an important 
role in the biosynthesis of serotorun and catecholamines (6 ). 
It is released exclusively from activated monocytes and mac-
rophages ( 7 ). The biologica1 significance ofneopterin is 80 far 
only poorly understood (8). Serum neopterin increased sig-
• Abbreviationa: DlC, diaeeminated intravaec:ular coagulation; 
TAT, thrombin-antithrombin III. 
nificantly 24 hr after TNF was administered to 6 healthy 
volunteers (9). The infuaion of TNF and IFN--y led to a aig-
nificant rise of neopterin 24 hr later in 24 patientB with 
advanced malignancies (10). The Iysosomal cysteine protein-
aee cathepsin B ia released from macropbages upon activa-
tion, as is the lysosomal serine proteinase elastase from poly-
morphonuclear granulocytes. 80th are believed to be 
important nonspecific mediators of inflammation (11). Fur· 
thermore. in previoua studies (12. 13), we bave proved their 
occulT1!nce in high ooncentrations in plasma during the re· 
perfusion phase of OLT. 
In OLT bleeding oomplications due to hyperfibrinolysis in 
theanhepatic phase (14-16), followed in the early reperfuaion 
phase by signs ofDIC (17,18) together with decreased plate-
let oount and platelet aggregability (J9. 20), are still alt.ering 
the patient'a outoome intra- and postoperatively. Recent in-
veatigations (14·16) have shown that hyperfibrinolysis ia 
most certainly due to an increased release and reduced clear· 
anre ofplaaminogen activators, and a oontinuoua intraopera· 
tive infusion of aprotinin, a proteina.se inhibitor (21). bas 
been demonstrated to reduce signa of increased fibrinolyaia 
88 weil as the bleed.ing tendency during OLT (22). However, 
the mechanism leading to DIC in the reperfusion phase is 
still lacking a pathophysiological explanation. 
Extending previoua investigationa (J2. 13), we investi-
gated the role of leukocyt..es in the pathogenesis of DIC in 
OLT by meaauring the mediators that they release upon ac-
tivation. We detennined levels of cathepsin B. elast.a&e, TNF, 
neopterin, and thrombin·antithrombin m (TAT) oomplexel 
before. during. and alter 13 OLTe. These data are OOlT1!lated 
for each time point of blood sampling to levels of aprotinin, 
which was given during and aft.er OLT. 
MATERIALS ANO METIlODS 
We inveatigated 13 patienta with t.enninalliver diseaae (Table 1) 
who underwent their firat OLT at the Univen.ity H06pital Rudolf 
Virebow. Berlin. Gennany. All 13 patienta were continuoualy treated 
with aprotinin infueion etarting with a doee of 200,000 KIUJhr with 
the induction of aneatheeia. whic:h wae increa.sed to 400.000 KlUIhr 
with the onset of the anhepatie phase until skin el06lU'e. Aprotinin 
W88 continued Wltil the thin! poatopentive day with 100.000 KlUI 
hr. Heparin WM etartecl at the end of the operation with 250 IUJhr 
and inerea.sed to 500 rulhr 12 hr later at le8,t. until the third post.-
operative day. OLT wu carried out by eatabliehed eurgica1 te<:h· 
niquea uaing 8 venovenoua bypaM. Plleked RBC and freah froun 
pl8llma wen! subetituted to compenaate for intra- and pot!Itopert.tive 
blood Ion. but neither plateleta nor concentrates of hemoetatie fac-
ton! were adminietered. Belzer UW·CSS .8Olution (Du Pont. Paril. 
France) was uaed during cold storage of the graft. liver (median 
duration of the cold etorlli'e time W8ll 11 hrl. 
Blood samplea were laken from the arterialline. aft..er induction er 
aneatheaia and before the lt.aTt of the operation (1). 5 nlin befoN (2) 
TAllLI! 1. Patient data 
Di6(lllOll;1 Female M., ... • Median Irani') 
P08tnecrotic cirrh08ie • 
, , 49 (24-65) 
Alcohol t.oxie cirrhoeil 1 0 1 47 
PrimaT)' bilia.ry 2 2 0 49.52 
cirrbosia 
PrimaT)' eclerotic 2 2 0 42.48 
cholangitil 
Th"" 13 • 5 46 (24-65) 
and 10 min afl.er (3) the beginning of tbe anhepatie stage. Further 
eamplee were collected 5 min before reperfu.ion (4 ), 811 weU aa 5 min 
(5). 15 min (6). and 60 min (7) aft.erwan!. Furthennore, aamplea were 
taken 12 hr (81. 36 hr (9), and 60 hr (10) afl.er the onaet of the 
reperfuaion phue. In addition. a eample of the perfuaate releaaed 
from the liver graft vein during the nuahing procedure with arterial 
blood W811 laken befon! opening ofhep8t.ocaval anaatomoeie and p0r-
tal blood flow. The t.otal volume oflhe perfusat.e ie appromnately 500 
ml and the perfuaat.e eample waa laken t.owaniH the end of the 
nuahing procedure. 
B100d eamplee were coJlected in plaatie Iyringea prefilled with 1110 
vol of trillOdium citrate. 
A8BOY~. TAT complexea were det.ennined by ELlSA (Behring 
Werke AG. Marbul'l, Germany). Cathepein B was me8llured by ita 
enzymatie activily againat the arrunopeptidase aubBtrate Z-Phe-Arg-
NMec (11). El8lltue wu estimated in compleJ: with al-proteinaBe 
inhibitor according t.o NeUJIUUUI et al. (23). 
Neapt.erin was eetimated by RlA (Henning. BerLin, Gennany) end 
TNF by immunoradiometrie 811I18Y (Medgenix DiagnOlltice, Fleurue. 
Belgiwn). Plaema IXIncentration of aprotinin were det.ermined by 
ELlSA 8CCOrding to MUller·EBt.erl et al. (24). 
SWutical analy.U. All the distribution of the parameten. W811 
found to be abnonnal (25). the nonparametrie WikoJ:on signed ranke 
telt was uaed for Itatietica1 evaluatioßl. Valuee of PsO.05 were con· 
aidered to be lignifiCMlt. Reaulta are given as median and range. 
RESULTS 
TAT oomplexes (Fig. 1) slowly iocreased during lhe prean· 
hepatic and anhepatic phases and ahowed a more prominent 
rise aft.er reperfuaion, with maxima1 levels 15 min af\.er re-
perfusion. This was foUowed by a steep decrease between 1 hr 
and 12 hr alter reperfusion and a le88 pronounced but aig-
nificant decrease between 12 hr and 60 hr. The perfusate 
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FlGURE 1. Median levels ofTAT complexee. TNF. neapt.erin. eathep-
ein B. and elaalase inhibitor (EPIl compleJ:es berore. during. and up 
to 3 daye aft.er OLT (for time pointa. eee Marerial~ and Meth.od& ). 
SignjfiCMltehangea between 2 time pointa an given 8IIP·valuea. TAT 
compleJ:ell: PHi'I)- O.OO2. P'H)E O.012. Pu/,,- O.04. Pfw,- 0.045. P,tI 
f1-0.009. P(1.t)-0.OO2. P,..""",O.OO2; TNF: P'Wl- O.02. PW'I,,,O.OO2. P," 
111)- 0.003; neopt.erin: P1 .... i'· 0.002. PI'" " 0.04. Pfll,,-O.003. P'M,-O,03; 
cathepein B: PfW,E O.OO2, P,tI'I)""O.02, PIl,.,=0.OO2; EPI complexea: 
p(l't)""O.03. P,w,-O.OO6. Pftl'l,- O.Ol. P
,7I1,·0.005. P,tIIo,-O.OO3. 
TABLE 2. Comparison of parameters in perfu8ate and systemic eirculstion 
Pa:ramfier 
TNF 
Neopterin 
Catheapin B 
Elsal.a8e 
TAT comple:r;ea 
Perfuaat..e 
Median ( Range) 
24 (2.5-1,020) 
79 (80-1,008) 
45,513 (976-624,265) 
761 (399-1,396) 
77 (32-1,300) 
levels of TAT complexes were tendentiously higher than in 
corresponding sampies taken 5 min before reperfusion (Table 
2). 
Levels ofTNF (Fig. 1) remained unchanged during prean-
hepatic and anhepatic phases. With revaacularization of the 
graft liver, a highly significant and sust.ained increase was 
seen, with maximal values 36 hr after reperfusion followed 
by a highly significant decrease. Tbe higher TNF concentra-
tion in the perfusate than in the systemic circulation 5 min 
before reperfusion was not significant (Table 2). 
Tbe concentration ofneopterin (Fig. 1) showed no changes 
during preanhepatic and anhepatic phases and increased sig-
nificantly with reperfusion of the graft, with maximal values 
5 min aft.er revascu1arization of the grall followed by a sig-
nificant decrease with minimum 1 hr after reperfusion and a 
second increase with maximal values 36 hr after reperfusion. 
Median levels measured in the perfusate reached more than 
15-fold higher concentrations than in the systemic circula-
tion before reperfusion, a difference that was highly signifi-
cant (Table 2). Cathepsin B (Fig. 1) increased highly signifi-
cantly with reperfusion reaching maximal levels 5 min after 
reperfusion followed by a significant decrease 10 min later 
reaching preoperative levels after 12 hr. Levels in the per-
fusste were excessively (440-fold) higher than in correspond-
ing sampies from the systemic circulation (Table 2). 
Concentration of elastase proteinase inhibitor complexes 
(Fig. 1) decreased significantly with the start ofthe anhepatic 
phase and increased highly significantly with reperfusion 
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FIGURE 2. Median levels of aprotinin before, during, and up to 3 
days aft.er OLT. Significant changea are given as P-valuea: pu ... ) 
=0.006, p("l/3 ) "0.03, P(~, '"'O. OO4, p(7"'''0.002, P(&'II)""O.04. 
Syltemie 
cimllaüon C"J 
Median (Range) 
16.6 (6.8-52.4) 
9.3 (5.!l-26.4) 
103.0 (55.7-204.4) 
604 (276-1,205) 
56 (17-381) 
p 
(Pt .. ) 
NS 
0.0022 
0.0022 
0.0499 
0.0995 
until maximal values were reached 60 min after the start of 
reperfusion, followed by a continuous decreasc. Levels in the 
perfusate were sigruficantly higher (1.3-fold) than in the sys-
temic circulation 5 min before reperfusion (Table 2). 
Significantly increasing levels of aprotinin (Fig. 2) were 
measurable throughout the whole OLT, with maximal values 
in the early and Jate reperfusion phase. No difference was 
observable in the perfusate and the cOITesponding systemic 
circulation. 
The plasma levels of thc markers of Icukocyte activation 
and prothrombin activation were correlated for each time 
point of plasma sampling (1-10 ) and for the perfusate. 
Significant correlations became apparent among TNF, 
neopterin, elastase, and cathepsin B, especially when con-
fined to reperfusion parameters (Fig. 3). Furthermore, a sig-
nificant correlation was observed between TAT complexes 
and the leukocytic mediators. Goly cathepsin B and TAT 
complexes did not correlate during and after OLT. Aprotinin 
levels did not correlate with most of the parameters investi-
gated. However, there was a correlation between neopterin 
and aprotinin that was tendentiously significant 5 min after 
reperfusion (P=0.098, r=O.5) and highly significant 36 hr 
TNF 
cathepsin B neopterin 
elastase ____ TAT 
6" 8' 10' 
(0.7, 0.15. 0.6) 
FIGURE 3. Correlat.ion among levels of cathepsin B, TNF, elsatase, 
neopterin, and TAT oomple:r;es snd the systemic circulation during 13 
OLT. Time point of blood eampling, aignificant level (+P<O.l , 
·P<O.05, "P<O.Ol), and oorrelstion roefficient (in parentheses) are 
given. 
(P=0.002, r=0.8) and tendent iously 60 hr (P=0.062, r=0.9) 
after the onset of reperfusion. 
With rega rd to the perfusate levels , a significant correla-
tion was observable between TNF levels and neopterin 
(P= 0.03, r = 0.6) as weil as between TAT oomplexes and elas· 
tase (P = 0.OO2, r = 0.8). 
D1SCUSSION 
Fift.een-fol~ elevated neopterin levels and 440-fold elevated 
cathepsin B levels in the perfusate together with a 100% 
increase of systemic neopterin levels and 700% increase of 
systemic cathepsin B with graft reperfusion suggest a neop· 
terin and cathepsin BreIease when blood passes the partially 
damaged vascular bed of the grat\. liver. 
This was paralleled by slightly, but significantly, elevated 
levels of elastase and tendentiously elevated levels of the 
marker of prothrombin activation, TAT complexes, in the 
perfusate. In the perfusate, TAT oomplexes and elaslase cor-
related significantly, suggesting an elastase-mediated in-
creased prothrombin activation in the graft. liver and an in-
dependent increase ofneopterin and C8thepsin B. 
In the systemic circulation, cathepsin B, elastase, TNF, 
and neopterin incressed s ignificantly, with sLarting reperfu. 
sion parallel to a significant increase in TAT complexes. In 
addition, with reperfusion of the graft Iiver there were cor-
relations between thc parameters of leukocyt.e activation as 
weil as TAT complexes. Only cathepsin B did not correlate 
with neopterin and TAT complexes. These results are an 
argument for a strong relationship between leukocyte acti-
vation and incressed thrombin generation with revascular-
ization of the Iiver grart so that the DIC-like state causing 
increased bleeding tendency in the reperfusion phase (15,17, 
18) may in part be initiated by leukocyte activation. The 
observed decrease in platelet count and platelet aggregability 
in the reperfusion phase (20 ) mayaIso be initiated by leuko-
cytic mediators. As correlations between leukocytic media-
tors as weil as TAT complexes are weak in the graft. liver's 
perfusate and 8trong in the systemic circulation (Fig. 3), the 
vascular bed of the patient's systemic circulation seems to be 
more important in initisting the release of leukocytic media-
tors than the graft liver's vessel wall. 
Levels of TNF and neopterin increase in parallel with re-
perfusion ofthe gran.. However, perfusate levels ofneopterin 
are much h ighe r than in the systemic circulation-a differ-
ence that is not seen with TNF. Tbe high neopterin levels do 
not, therefore, seem to be induced primarily by TNF (9 ), but 
by a direct activation of monocytes. However, a TNF -medi-
sted activation of the monocytes may sccondarily contribut.e 
to the high levels of neopterin. 
Recently, it has been demonstrated that elevated TNF lev· 
eIs up to 100 pglml at the end of OLT were preceding graft. 
rejection within 10 days after OLT (5 ). In our investigated 
group of 13 patients, no graft rejection occurred postopera-
tively and TNF levels higher than 100 pg/ml were measur· 
able at the end of the operation in 2 patients only. 
A highly significant correlation was seen between aproti-
nin levels and neopterin 36 hr and 60 hr aller reperfusion, 
whereas none of the other parameters seem influenced by 
aprotinin. This may be eJlplained by a retarded host reaction 
against aprotinin as bovine protein. 
In oonclusion, our results strongly indicate arelease of 
leukocytic mediators out ofthe graftliver during its reperfu-
sion which seems to be oonnected to the parallely increased 
prothrombin activation. Aprotinin did not completely control 
the release ofleukocytic media tors. For ethical reasons, there 
was no control group of patients without aprotinin treatment 
during OLT, 8{l that nothing can be said about the potential 
effect of aprotinin. 
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